PreprintAll rights reservedmedRxiv
Genome Profiling of Actionable Cancer Targets (NYU LG-PACT) for Clinical Patient Molecular Diagnostics and Treatment
- 1NYU Langone Health, Department of Pathology, Molecular Pathology and Diagnostics, 240 East 38th Street, New York, NY 10016
Related
- Comprehensive Molecular Profiling for Precision Diagnostics: Integrating Genomic, Proteomic, and Epigenetic Landscapes in Human Pathology
- 974 Integrated multimodal profiling reveals conserved type II interferon signalling, ectopic lymphoid structure formation, and actionable inflammatory endotypes in cutaneous immune-related adverse events
- Clinical Utility of lncRNAs in Urothelial Carcinoma of the Bladder: Diagnostics, Risk Stratification, and Treatment Guidance
- Molecular profiling and access to treatment for rare cancers in Europe
- Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling
BibTeX
@misc{yang2026genome,
title = {{Genome Profiling of Actionable Cancer Targets (NYU LG-PACT) for Clinical Patient Molecular Diagnostics and Treatment}},
author = {Y. Yang and V. Vasudevaraja and J. Serrano and H. Mohamed and S. Kelly and G. Jour and T. Gindin and K. Park and D. Jones and X. Feng and J. Pinnell and S. Mclennan and M. Y. Tin and A. Tsirigos and M. Snuderl and K. O. Wrzeszczynski},
howpublished = {medRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.27.26361341},
url = {https://www.medrxiv.org/content/10.64898/2026.08.27.26361341v1},
}
RIS
TY - UNPB
TI - Genome Profiling of Actionable Cancer Targets (NYU LG-PACT) for Clinical Patient Molecular Diagnostics and Treatment
AU - Y. Yang
AU - V. Vasudevaraja
AU - J. Serrano
AU - H. Mohamed
AU - S. Kelly
AU - G. Jour
AU - T. Gindin
AU - K. Park
AU - D. Jones
AU - X. Feng
AU - J. Pinnell
AU - S. Mclennan
AU - M. Y. Tin
AU - A. Tsirigos
AU - M. Snuderl
AU - K. O. Wrzeszczynski
PY - 2026
DA - 2026/08/27
PB - medRxiv
DO - 10.64898/2026.08.27.26361341
UR - https://www.medrxiv.org/content/10.64898/2026.08.27.26361341v1
ER -